JPRN-UMIN000041546已完成未知
Effect of daprodustat on renal anemia in patients with chronic kidney disease - Effect of daprodustat on renal anemia
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
The median dose of darbepoetin before switching was 40 micrograms/wk, and all subjects received daprodustat 4 mg orally once daily at the time of switching. After that, the dose of daprodustat was adjusted appropriately to achieve the guideline target Hb of 10-12g/dL. Hb was 10.9 + 0.4(SE)g/dL when switched to daprodustat. Hb levels did not change significantly until 12 months and were maintained at 10-12g/dL.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients complicated with serious diseases such as malignancy, heart failure (NYHA III degrees or more), and liver cirrhosis
研究者
相似试验
已完成
不适用
The effect of Darbepoetin for renal anemia and iron kinetics in Chronic Kidney Disease(CKD) patientsChronic kidney disease and renal anemiaJPRN-UMIN000005068Yamamoto General Hospital20
已完成
不适用
Effect of roxadustat on renal anemia in hemodialysis patientsEnd-stage renal diseaseJPRN-UMIN000039598Saitama Tsukinomori Clinic18
已完成
3 期
A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)AnaemiaNCT02969655GlaxoSmithKline271
已完成
不适用
Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal AnemiaPeritoneal Dialysis, Continuous AmbulatoryAnemiaKidney Failure, ChronicNCT00563446Hospital Authority, Hong Kong16
招募中
Unknown
Renal Anemia Treatment with Roxadustat for Non-dialysis Patients with Lower Extremity Artery Disease: The REFINE trialJPRN-jRCTs031230506eki Yasushi100